Regulators Struggle to Keep Pace with AI-Powered Medical Devices

Regulators are scrambling to keep pace with rapid advancements in AI-powered medical devices. The stakes have grown higher as more doctors rely on algorithms for diagnoses.

The UK's National Commission into the Regulation of AI in Healthcare issued a 44-point plan last September, calling for a fundamental overhaul of how AI-powered medical devices get approved and monitored. The US FDA released its own discussion paper on generative AI medical devices earlier this year.

In a significant departure from the traditional approval model, the UK commission proposes a lifecycle-based, risk-proportionate system. This would involve 'L-plate' authorizations, staged approvals where AI systems operate under supervision before earning full clearance. The framework also calls for continuous monitoring of real-world performance and public access to safety data.

The FDA's discussion paper focuses on generative AI-enabled medical devices, outlining a competency-based framework that covers risk assessment, premarket evaluation, and postmarket monitoring. Public comments are due by October 19th. Individual US states have also taken action, passing laws mandating human oversight for AI used in therapy and psychotherapy applications.

The European Union's AI Act classifies many medical AI systems as high-risk, triggering compliance obligations around transparency, data governance, and human oversight. Full high-risk obligations won't be enforced until 2027-28.